Response to pegylated interferon in a COVID-19-positive elderly woman with primary myelofibrosis treated with ruxolitinib

Arthur E Frankel, Renuka Reddy, Kayla R DeSuza, Khaled Deeb, Aaron F Carlin, Davey Smith, Yushuang Xie, Eknath Naik, Richard T Silver, Hans C Hasselbalch

Publikation: Bidrag til tidsskriftArtikelForskningpeer review

Abstrakt

An 83-year-old female had asymptomatic SARS-CoV-2 infection while taking ruxolitinib. She remained RT-PCR positive for viral RNA for >120 days, and Pegylated interferon for 4 weeks led to viral RNA clearance. The observations support combination therapy of ruxolitinib + interferon for COVID-19.

OriginalsprogEngelsk
Sider (fra-til)2228-2235
Antal sider8
TidsskriftClinical Case Reports
Vol/bind9
Udgave nummer4
DOI
StatusUdgivet - apr. 2021

Bibliografisk note

© 2021 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.

Fingeraftryk

Udforsk hvilke forskningsemner 'Response to pegylated interferon in a COVID-19-positive elderly woman with primary myelofibrosis treated with ruxolitinib' indeholder.

Citationsformater